about
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutationsThe Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors-Is Pharmacogenetics the Key?NRAS-mutant melanoma: response to chemotherapy.Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaPD-1 and PD-L1 antibodies for melanoma31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneAnti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialResults of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignanciesPhase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma.A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialPhase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorReplacement of administration sets (including transducers) for peripheral arterial catheters: a systematic review.Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.Detection of medical errors in kidney transplantation: a pilot study comparing proactive clinician debriefings to a hospital-wide incident reporting system.Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanomaDissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunityPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanomaClinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.Clinical outcomes and quality of life in recipients of livers donated after cardiac deathThe combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.MIIB: A Metric to Identify Top Influential Bloggers in a Community.P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study.In vitro evaluation of Moringa oleifera gum for colon-specific drug delivery.Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.Applying the WHO conceptual framework for the International Classification for Patient Safety to a surgical populationPhase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
P50
Q24632064-67CAA855-BD96-4772-910A-11C377496255Q26741187-052F1532-C634-4DB0-9796-A5D97F43CC62Q27851647-0E6B9F13-7C24-4BDA-BBE9-838028DAAA05Q27853216-60A7A1E9-AA57-43BF-A410-735003615169Q27853379-CC2539E6-10F2-48CF-B7FC-753B2091FD1DQ27860650-14661A04-443E-46DB-9101-66275A52790BQ28081882-B08AC9EF-D1D4-47EB-8DED-B5756B319D1FQ28553703-6BE68F92-C250-4AFD-AC1C-4A85786ADAFAQ29620814-C6282DE2-25E2-4924-A02E-69378A9072EBQ33384029-AA55403A-D5E5-4BFE-AA7C-AF3AFF0A14AAQ33397618-678F9074-B303-4A44-831C-28999CFBB4C0Q33419897-EEE693AD-58E4-4B64-B5B8-18130E205495Q33424674-8A97E682-FEC2-4EC7-9E31-CCF169E3FB58Q33430193-9844AEA0-F4E7-4EF9-A204-2FCD56679DB1Q33564516-EC42C527-011F-4F43-9404-F3FE0BAA6A26Q33749057-29A3E8D1-C6F1-4388-8A02-A2F9FD2760BDQ34241419-63B36217-E509-4B67-9C69-D0634BBF466FQ34484174-037B64B1-4E8A-4BB9-B737-1AECA9AB5564Q34508627-8514B398-EA3C-4605-AD60-B68CBEA0AE0AQ34594791-99B96830-7CE5-4C81-8221-86D81B589FFCQ34625045-556391D1-F45E-45C7-93B9-1D90798C2C95Q34625311-FA6E5C98-CE60-45B0-ACA0-E54C6D7F8E12Q34625640-F5C9CC43-2FF0-4619-98CC-F5CA61D48C19Q34670965-987A13A6-5BCA-4B07-9E9C-D63A342BA79FQ34887442-D12D4CBE-F151-42AE-9581-078BF52398FCQ34968336-31C91800-1C3C-4835-AD7B-131FE3CB3A74Q34980474-AF926E9B-CD50-41B0-A978-9D9CFA7D013CQ35422315-EEB26539-7A87-4ECA-83BC-CA3A507F078DQ35475284-ADB72281-F0D7-4F33-BB57-AD64B151F3D9Q35790367-7D38CF42-85B5-4825-BCCB-F870381A1786Q35802617-80F4B9CA-447D-4BD6-8F39-3D9C29ADA87DQ36300208-B543F046-CBD7-4331-A924-004B4B48DDFAQ36306228-BEE7F67A-79FD-45BA-844F-C98CE993F0D9Q36802238-6DD4FD92-BA38-44A9-97AA-9B4DE95E4C2EQ36934286-0BCC04A0-DD67-44E0-B0CD-ADEB65DD0B3AQ37068863-0C924F87-CD9A-4938-A12A-CA5D9074A4D7Q37271951-616FC749-DBC9-4932-8E45-7CF5D1817101Q37333908-DCE86140-BA0F-45E8-86F1-9D27E680FADDQ37350763-BA6698A1-EEBB-4F35-9BA3-B656CF3F8846Q37400592-74086B10-2193-432F-96A8-2E5776997D53
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Adil Daud
@ast
Adil Daud
@en
Adil Daud
@es
Adil Daud
@nl
Adil Daud
@sl
type
label
Adil Daud
@ast
Adil Daud
@en
Adil Daud
@es
Adil Daud
@nl
Adil Daud
@sl
prefLabel
Adil Daud
@ast
Adil Daud
@en
Adil Daud
@es
Adil Daud
@nl
Adil Daud
@sl
P106
P31
P496
0000-0002-6617-8421